Physician profile
Robert Eric Sarche
NPI 1144224528
$4,056.96
in general payments reported to CMS, 2019-2025
44 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $214 · 2021: $76.31 · 2022: $1,580 · 2023: $27.42 · 2024: $413 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $736.19 | 2019-2022 | |
| Abbvie INC. | $521.98 | 2019-2025 | |
| Pfizer INC. | $308.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $274.10 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $189.87 | 2019-2025 | Wegovy |
| Grifols USA, LLC | $150.35 | 2019-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $150.04 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $137.17 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $133.53 | 2019-2020 | |
| Amgen INC. | $128.69 | 2019-2025 | Evenity, Repatha, Prolia |
| Otsuka America Pharmaceutical, INC. | $126.05 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $122.49 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.37 | 2022 | |
| Merck Sharp & Dohme LLC | $73.20 | 2019-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Shield Therapeutics INC | $72.86 | 2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sarche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.